// App-Quantinova.ai

4084 : Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).

Researchers

Presenter

  • Andrew X. Zhu

Principal Investigators

  • Masahiro Kobayashi

  • Masafumi Ikeda

  • Marc Pracht

  • Max W. Sung

  • Ari David Baron

  • Masatoshi Kudo

  • Tim Meyer

  • Takuji Okusaka

  • Hiromitsu Kumada

  • Shuichi Kaneko

  • Taisuke Hoshi

  • Kenichi Saito

  • Shuyu D Li

  • Yasuhiro Funahashi

  • Yukinori Minoshima

  • Leonid Dubrovsky

  • Richard S. Finn

Medical Centers

  • Massachusetts General Hospital Cancer Center and Jiahui International Cancer...

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Toranomon Hospital, Tokyo, Japan

  • National Cancer Center, EPOC, Chiba, Japan

  • Centre Eugene-Marquis, Rennes, France

  • Tisch Cancer Institute at Mount Sinai, New York, NY

  • California Pacific Medical Center, San Francisco, CA

  • Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • National Cancer Center Hospital, Tokyo, Japan

  • Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan

  • Eisai Co. Ltd., Tsukuba, Ibaraki, Japan

  • Eisai Inc, Woodcliff Lake, NJ

  • Eisai Co. Ltd. Bunkyo, Tokyo, Japan

  • Merck & Co., Inc., Kenilworth, NJ

  • David Geffen School of Medicine, UCLA Medical Center, Los Angeles, CA

Locations

  • United States

  • Japan

  • France

  • United Kingdom

Companies

  • Eisai Co., Ltd.

  • Eisai Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

  • Sorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT03006926

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved